Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9747419 | 0.88 | ABCB11 (0.74) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Nepafenac SCHEMBL29377340 | 0.86 | ABCB11 (0.62) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Nepafenac SCHEMBL93835 | 0.86 | ABCB11 (0.62) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| SCHEMBL7178368 | 0.85 | ABCB11 (0.79) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| SCHEMBL94129 | 0.85 | ABCB11 (0.58) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| SCHEMBL11227912 | 0.85 | ABCB11 (0.54) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| Water SCHEMBL11470789 | 0.85 | — | — | |
| SCHEMBL10903139 | 0.82 | ABCB11 (0.51) | ABCB11LMNAPTGS1ADORA1PTGS2 | |
| SCHEMBL11227211 | 0.82 | MAPK14 (0.50) | — | |
| SCHEMBL10999128 | 0.81 | ALDH1A1 (0.46) | ABCB11LMNAPTGS1ADORA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101426487-B | Formulations containing amide derivatives of carboxylic acidnsaids for topical administration to the eye | ALCON INC | 2011-04-06 | — | — | CN | claimed |
| CN-101426487-A | Formulations containing amide derivatives of carboxylic acidnsaids for topical administration to the eye | ALCON INC (CH) | 2009-05-06 | — | — | CN | claimed |
| EP-2012767-A2 | FORMULATIONS CONTAINING AMIDE DERIVATIVES OF CARBOXYLIC ACID NSAIDS FOR TOPICAL ADMINISTRATION TO THE EYE | ALCON INC. (CH) | 2009-01-14 | — | — | EP | claimed |
| WO-2007127844-A2 | FORMULATIONS CONTAINING AMIDE DERIVATIVES OF CARBOXYLIC ACID NSAIDS FOR TOPICAL ADMINISTRATION TO THE EYE | ALCON, INC. (CH) | 2007-11-08 | — | — | WO | claimed |
| US-20070254939-A1 | Formulations Containing Amide Derivatives of Carboxylic Acid NSAIDS for Topical Administration to the Eye | ALCON, INC. (CH) | 2007-11-01 | — | — | US | claimed |
| EP-1309323-B1 | TREATMENT OF ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID DERIVATIVES | ALCON INC (CH) | 2006-11-15 | — | — | EP | claimed |
| EP-1309322-B1 | USE OF 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR THE TREATMENT OF RETINAL DISORDERS | ALCON INC (CH) | 2006-06-21 | — | — | EP | claimed |
| JP-2004520267-A | — | — | 2004-07-08 | — | — | JP | claimed |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALCON, INC. (CH) | 2004-07-08 | — | — | US | claimed |
| US-6646001-B2 | Administering to a glaucoma affected eye a combination of an intraocular pressure lowering prostaglandin FP receptor agonist, and a prostaglandin synthesis inhibitor other than diclofenac or fluorometholone | ALCON MANUFACTURING, LTD. | 2003-11-11 | — | — | US | claimed |
| EP-0716600-B1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LAB INC (US) | 2002-04-03 | — | — | EP | claimed |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | ALCON UNIVERSAL LTD. | 2002-03-28 | — | — | US | claimed |
| WO-2002013805-A2 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS OF THE RETINA AND OPTIC NERVE HEAD | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | claimed |
| WO-2002013804-A2 | METHOD OF TREATING ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | claimed |
| US-6342524-B1 | TREATMENT OF GLAUCOMA WITH PROSTAGLANDINS | ALCON MANUFACTURING, LTD. | 2002-01-29 | — | — | US | claimed |
| CN-1129397-A | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | ALCON LAB INC (US) | 1996-08-21 | — | — | CN | claimed |
| EP-0716600-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1996-06-19 | — | — | EP | claimed |
| WO-1995033457-A1 | TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING 3-BENZOYLPHENYLACETIC ACID DERIVATIVES FOR TREATMENT OF OPHTHALMIC INFLAMMATORY DISORDERS | ALCON LABORATORIES, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| US-5475034-A | Adminstering 3-benzoylphenylacetamide derivatives | ALCON LABORATORIES, INC. (US) | 1995-12-12 | — | — | US | claimed |
| US-4313949-A | Method of producing an inhibitory effect on blood platelet aggregation | A. H. ROBINS COMPANY, INC. (US) | 1982-02-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALDH1A2, GAP43, NLN | ABCB11 3404/4885LMNA 655/4885PTGS1 341/4885 |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | MME, FLT4, EYA3 | ABCB11 3980/4885LMNA 626/4885PTGS1 202/4885 |
| US-20070254939-A1 | Formulations Containing Amide Derivatives of Carboxylic Acid NSAIDS for Topical Administration to the Eye | NDUFAB1, CS, SLC25A1 | ABCB11 1856/4885LMNA 3942/4885PTGS1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.